Infervision Group is assumed that since 2015, the team has devoted itself to
the application of artificial intelligence deep learning technology in medical
imaging. The deep learning technology is used to analyze DR, CT and MRI medical
image data, providing doctors with accurate and efficient assistant tools,
reducing the burden of doctors'work and returning doctors to the diagnosis
itself.
Since the establishment of Beijing Hypothesis Technology Co., Ltd. in January
2016, the execution points at home and abroad have covered many cities in China.
At the same time, the strategic layout of North America, Asia-Pacific and Europe
has been completed. In November 2018, the Global Institute of Hypothesis
Technology for Clinical Research (iCR) was established to promote the
integration of medical AI and clinical science.
Infervision Group is assumed that science and technology has nearly 60% of
R&D staff, including outstanding talents from the Chinese Academy of
Sciences, Tsinghua, Chicago, Cambridge, Duke, University of California, Los
Angeles and other well-known institutions.
Infervision Group upholds the principle of "from clinic to clinic", listens
to the needs of doctors and thinks of doctors. At present, it has established
cooperation with more than 250 hospitals at home and abroad, assisting doctors
to complete nearly 25,000 clinical diagnoses every day. Presumption is that
InferRead CT lung disease solution has developed into a large-scale auxiliary
diagnostic system. In a large third-level hospital using 30 days of operation
data, 22065 cases predicted that none of the missed diagnosis performance is to
assume the excellent answer of technology AI.
